"Triazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heterocyclic rings containing three nitrogen atoms, commonly in 1,2,4 or 1,3,5 or 2,4,6 formats. Some are used as HERBICIDES.
Descriptor ID |
D014227
|
MeSH Number(s) |
D03.383.931
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Triazines".
Below are MeSH descriptors whose meaning is more specific than "Triazines".
This graph shows the total number of publications written about "Triazines" by people in this website by year, and whether "Triazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 1 | 1 | 2 |
1997 | 1 | 2 | 3 |
2000 | 1 | 0 | 1 |
2005 | 1 | 1 | 2 |
2006 | 2 | 0 | 2 |
2007 | 3 | 0 | 3 |
2008 | 1 | 0 | 1 |
2009 | 2 | 0 | 2 |
2010 | 2 | 1 | 3 |
2011 | 1 | 0 | 1 |
2012 | 1 | 2 | 3 |
2014 | 1 | 1 | 2 |
2018 | 0 | 1 | 1 |
2019 | 1 | 0 | 1 |
2020 | 2 | 1 | 3 |
2021 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Triazines" by people in Profiles.
-
Revisiting biochemistry: severe euglycemic ketoacidosis in the setting of IDH-inhibitor therapy for AML. Br J Haematol. 2021 09; 194(6):1083-1085.
-
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021 04 01; 137(13):1792-1803.
-
Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). Am J Clin Pathol. 2020 11 04; 154(6):731-741.
-
Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir. Transpl Infect Dis. 2020 Aug; 22(4):e13336.
-
Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.
-
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. Eur J Cancer. 2019 10; 120:132-139.
-
Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. Cancer Med. 2018 11; 7(11):5478-5487.
-
First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors. J Hematol Oncol. 2016 Mar 10; 9:23.
-
Inhibition of phosphodiesterase 2 reverses impaired cognition and neuronal remodeling caused by chronic stress. Neurobiol Aging. 2015 Feb; 36(2):955-70.
-
3D real-time intracardiac echocardiographic visualization of atrial structures relevant to atrial fibrillation ablation. JACC Cardiovasc Imaging. 2014 Jan; 7(1):97-100.